134 related articles for article (PubMed ID: 3884019)
1. Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis.
Williams HJ; Furst DE; Dahl SL; Steen VD; Marks C; Alpert EJ; Henderson AM; Samuelson CO; Dreyfus JN; Weinstein A
Arthritis Rheum; 1985 Mar; 28(3):308-14. PubMed ID: 3884019
[TBL] [Abstract][Full Text] [Related]
2. The effect of percutaneous dimethyl sulfoxide on cutaneous manifestations of systemic sclerosis.
Scherbel AL
Ann N Y Acad Sci; 1983; 411():120-30. PubMed ID: 6576688
[TBL] [Abstract][Full Text] [Related]
3. Failure of dimethyl sulfoxide in the treatment of scleroderma.
Binnick SA; Shore SS; Corman A; Fleischmajer R
Arch Dermatol; 1977 Oct; 113(10):1398-402. PubMed ID: 911168
[TBL] [Abstract][Full Text] [Related]
4. Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma.
Shirley HH; Lundergan MK; Williams HJ; Spruance SL
Pharmacotherapy; 1989; 9(3):165-8. PubMed ID: 2755866
[TBL] [Abstract][Full Text] [Related]
5. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.
Matucci-Cerinic M; Denton CP; Furst DE; Mayes MD; Hsu VM; Carpentier P; Wigley FM; Black CM; Fessler BJ; Merkel PA; Pope JE; Sweiss NJ; Doyle MK; Hellmich B; Medsger TA; Morganti A; Kramer F; Korn JH; Seibold JR
Ann Rheum Dis; 2011 Jan; 70(1):32-8. PubMed ID: 20805294
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of long-term use of dimethyl sulfoxide in the complex treatment of patients with systemic scleroderma].
Murav'ev IuV; Aliab'eva AP; Sigidin IaA; Guseva NG; Balabanova RM
Ter Arkh; 1985; 57(8):125-7. PubMed ID: 3906994
[No Abstract] [Full Text] [Related]
7. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
[TBL] [Abstract][Full Text] [Related]
8. Topical phenytoin suspension and normal saline in the treatment of leprosy trophic ulcers: a randomized, double-blind, comparative study.
Bhatia A; Nanda S; Gupta U; Gupta S; Reddy BS
J Dermatolog Treat; 2004 Sep; 15(5):321-7. PubMed ID: 15370401
[TBL] [Abstract][Full Text] [Related]
9. Bosentan for digital ulcers in patients with systemic sclerosis.
Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
[TBL] [Abstract][Full Text] [Related]
10. Discussion paper: methodology and techniques in the evaluation of dimethyl sulfoxide for connective tissue disorders.
Fleischmajer R
Ann N Y Acad Sci; 1975 Jan; 243():393-4. PubMed ID: 1055555
[No Abstract] [Full Text] [Related]
11. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
Gholam P; Sehr T; Enk A; Hartmann M
Dermatology; 2009; 219(2):171-3. PubMed ID: 19590168
[TBL] [Abstract][Full Text] [Related]
12. Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma).
Ozgocmen S; Kaya A; Coskun BK
Clin Rheumatol; 2006 May; 25(3):378-9. PubMed ID: 16211339
[No Abstract] [Full Text] [Related]
13. Multiclinic study of DMSO for systemic sclerosis.
Scherbel AL
Arthritis Rheum; 1985 Dec; 28(12):1437-8. PubMed ID: 3910051
[No Abstract] [Full Text] [Related]
14. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
[TBL] [Abstract][Full Text] [Related]
15. Management of sclerodermal finger ulcers.
Gahhos F; Ariyan S; Frazier WH; Cuono CB
J Hand Surg Am; 1984 May; 9(3):320-7. PubMed ID: 6725888
[TBL] [Abstract][Full Text] [Related]
16. Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan.
Zelenietz C; Pope J
Ann Rheum Dis; 2010 Nov; 69(11):2055-6. PubMed ID: 20959328
[No Abstract] [Full Text] [Related]
17. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
[TBL] [Abstract][Full Text] [Related]
18. New hope for systemic sclerosis patients with digital ulcers.
Varga J
Curr Rheumatol Rep; 2005 Apr; 7(2):127-8. PubMed ID: 15760591
[No Abstract] [Full Text] [Related]
19. Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
Kurgyis Z; Varga R; Sick I; Lang MU; Ruzicka T; Sárdy M
Acta Derm Venereol; 2011 Oct; 91(6):716-7. PubMed ID: 21879251
[No Abstract] [Full Text] [Related]
20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
